{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:40:59Z","timestamp":1791726059825,"version":"4.3.4"},"reference-count":397,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM142866"],"award-info":[{"award-number":["R35GM142866"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32-GM133395"],"award-info":[{"award-number":["T32-GM133395"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.addr.2023.114831","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T01:59:03Z","timestamp":1682301543000},"page":"114831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Aerosol pulmonary immune engineering"],"prefix":"10.1016","volume":"199","author":[{"given":"Emma R.","family":"Sudduth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trautmann-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Bomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7528-0997","authenticated-orcid":false,"given":"Catherine A.","family":"Fromen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114831_b0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jamp.2016.1297","article-title":"The history of therapeutic aerosols: a chronological review","volume":"30","author":"Stein","year":"2016","journal-title":"J. Aerosol Med. Pulmon. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0015","series-title":"Mechanical Ventilation Amid the COVID-19 Pandemic: A Guide for Physicians and Engineers","first-page":"5","article-title":"An Overview of Lung Anatomy and Physiology","author":"Katrivesis","year":"2022"},{"key":"10.1016\/j.addr.2023.114831_b0020","series-title":"West's Respiratory Physiology: The Essentials","author":"West","year":"2016"},{"key":"10.1016\/j.addr.2023.114831_b0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12931-019-1239-z","article-title":"Strategies for measuring airway mucus and mucins","volume":"20","author":"Atanasova","year":"2019","journal-title":"Respirat. Res."},{"key":"10.1016\/j.addr.2023.114831_b0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00418-018-1747-9","article-title":"The micromechanics of lung alveoli: structure and function of surfactant and tissue components","volume":"150","author":"Knudsen","year":"2018","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.addr.2023.114831_b0035","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1164\/rccm.200308-1107OC","article-title":"The number of alveoli in the human lung","volume":"169","author":"Ochs","year":"2004","journal-title":"Am. J. Respirat. Crit. Care Med."},{"key":"10.1016\/j.addr.2023.114831_b0040","doi-asserted-by":"crossref","first-page":"e1158","DOI":"10.1002\/cti2.1158","article-title":"What lies beneath the airway mucosal barrier? Throwing the spotlight on antigen-presenting cell function in the lower respiratory tract","volume":"9","author":"Pai","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0045","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mi.2013.14","article-title":"Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections","volume":"6","author":"Guilliams","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/imm.13143","article-title":"Tissue-resident innate immunity in the lung","volume":"159","author":"Ardain","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2023.114831_b0055","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1183\/09031936.00141514","article-title":"The innate immune function of airway epithelial cells in inflammatory lung disease","volume":"45","author":"Hiemstra","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.addr.2023.114831_b0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejpb.2019.11.005","article-title":"Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems","volume":"146","author":"Woods","year":"2020","journal-title":"Eur. J. Pharmaceut. Biopharm."},{"key":"10.1016\/j.addr.2023.114831_b0065","series-title":"Proteases in Human Diseases","first-page":"333","article-title":"Role of Proteases in Lung Disease: A Brief Overview","author":"Chakraborti","year":"2017"},{"key":"10.1016\/j.addr.2023.114831_b0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ni.3052","article-title":"The development and function of lung-resident macrophages and dendritic cells","volume":"16","author":"Kopf","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nri3600","article-title":"Alveolar macrophages: plasticity in a tissue-specific context","volume":"14","author":"Hussell","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41385-021-00480-w","article-title":"The impact of the lung environment on macrophage development, activation and function: diversity in the face of adversity","volume":"15","author":"Bain","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5160794","article-title":"Lung interstitial macrophages: past present, and future","volume":"2018","author":"Schyns","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.addr.2023.114831_b0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1165\/rcmb.2016-0361OC","article-title":"Three unique interstitial macrophages in the murine lung at steady state","volume":"57","author":"Gibbings","year":"2017","journal-title":"Am. J. Respirat. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2023.114831_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753940","article-title":"Diversity of macrophages in lung homeostasis and diseases","volume":"12","author":"Hou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-physiol-020518-114630","article-title":"Innate lymphoid cells of the lung","volume":"81","author":"Barlow","year":"2019","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.addr.2023.114831_b0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41385-018-0130-4","article-title":"Pulmonary group 2 innate lymphoid cells: surprises and challenges","volume":"12","author":"Starkey","year":"2019","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00861","article-title":"Innate lymphoid cells in mucosal immunity","volume":"10","author":"Panda","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40779-016-0093-2","article-title":"The origin and role of innate lymphoid cells in the lung","volume":"3","author":"Lai","year":"2016","journal-title":"Military Med. Res."},{"key":"10.1016\/j.addr.2023.114831_b0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1513\/pats.200507-070JS","article-title":"Cell-mediated adaptive immune defense of the lungs","volume":"2","author":"Curtis","year":"2005","journal-title":"Proc. Am. Thoracic Soc."},{"key":"10.1016\/j.addr.2023.114831_b0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-immunol-032712-100019","article-title":"T cell-mediated host immune defenses in the lung","volume":"31","author":"Chen","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00992","article-title":"Lung tissue resident memory T-cells in the immune response to Mycobacterium tuberculosis","volume":"10","author":"Ogongo","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ni.3056","article-title":"Antiviral B cell and T cell immunity in the lungs","volume":"16","author":"Chiu","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.852546","article-title":"The role of IgA in chronic upper airway disease: friend or foe?","volume":"3","author":"S\u00e1nchez Montalvo","year":"2022","journal-title":"Front. Allergy"},{"key":"10.1016\/j.addr.2023.114831_b0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/imm.12764","article-title":"Lung-resident \u03b3\u03b4 T cells and their roles in lung diseases","volume":"151","author":"Cheng","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.addr.2023.114831_b0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines \u2014 fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/jamp.2011.0931","article-title":"Pulmonary Vaccine Delivery: A Realistic Approach?","volume":"25","author":"Tonnis","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2005.05.028","article-title":"Pulmonary DNA vaccination: Concepts, possibilities and perspectives","volume":"107","author":"Bivas-Benita","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b0165","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114831_b0170","unstructured":"C.C.f.S.S.a. Engineering, COVID-19 Dashboard, Johns Hopkins University."},{"key":"10.1016\/j.addr.2023.114831_b0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1165\/rcmb.2011-0070OC","article-title":"Mouse Lung CD103+ and CD11bhigh Dendritic Cells Preferentially Induce Distinct CD4+ T-Cell Responses","volume":"46","author":"Furuhashi","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.addr.2023.114831_b0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pharmthera.2004.11.004","article-title":"Molecular regulation of Th2 immunity by dendritic cells","volume":"106","author":"Grunig","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1165\/rcmb.2007-0237OC","article-title":"Lung Dendritic Cells Have a Potent Capability to Induce Production of Immunoglobulin A","volume":"38","author":"Naito","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.addr.2023.114831_b0190","doi-asserted-by":"crossref","DOI":"10.1186\/s12948-017-0077-0","article-title":"Immunosenescence in aging: between immune cells depletion and cytokines up-regulation","volume":"15","author":"Ventura","year":"2017","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.addr.2023.114831_b0195","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.addr.2023.114831_b0200","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/rccm.200410-1384SO","article-title":"Pulmonary dendritic cells","volume":"172","author":"Vermaelen","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.addr.2023.114831_b0205","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s12551-017-0319-x","article-title":"New perspectives in nanotherapeutics for chronic respiratory diseases","volume":"9","author":"da Silva","year":"2017","journal-title":"Biophys Rev"},{"key":"10.1016\/j.addr.2023.114831_b0210","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2023.114831_b0215","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.cell.2021.03.005","article-title":"The aging lung: Physiology, disease, and immunity","volume":"184","author":"Schneider","year":"2021","journal-title":"Cell"},{"issue":"Suppl 2","key":"10.1016\/j.addr.2023.114831_b0220","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1513\/AnnalsATS.201503-126AW","article-title":"Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease","volume":"12","author":"Bhat","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2023.114831_b0225","unstructured":"A. AK., R. A., B. BD., Chronic Obstructive Pulmonary Disease, StatPearls2022."},{"key":"10.1016\/j.addr.2023.114831_b0230","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2023.114831_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797292","article-title":"Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis","volume":"12","author":"Mei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2023.114831_b0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/crj.13466","article-title":"Idiopathic pulmonary fibrosis: Current and future treatment","volume":"16","author":"Glass","year":"2022","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.addr.2023.114831_b0245","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: Basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Animal Model Exp Med"},{"key":"10.1016\/j.addr.2023.114831_b0250","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1159\/000446825","article-title":"Cystic fibrosis lung immunity: the role of the macrophage","volume":"8","author":"Bruscia","year":"2016","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.addr.2023.114831_b0255","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.addr.2023.114831_b0260","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.114831_b0265","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s12094-018-02011-9","article-title":"The role of immunotherapy in small cell lung cancer","volume":"21","author":"Calles","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.addr.2023.114831_b0270","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2021.635194","article-title":"The Proposition of the Pulmonary Route as an Attractive Drug Delivery Approach of Nano-Based Immune Therapies and Cancer Vaccines to Treat Lung Tumors","volume":"3","author":"Donkor","year":"2021","journal-title":"Frontiers in Nanotechnology"},{"key":"10.1016\/j.addr.2023.114831_b0275","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jconrel.2013.10.012","article-title":"Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents","volume":"172","author":"Jia","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b0280","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/resp.12789","article-title":"Immunotherapy for lung cancer","volume":"21","author":"Steven","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.addr.2023.114831_b0285","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/ijms21020597","article-title":"Immunosurveillance and immunoediting of lung cancer: current perspectives and challenges","volume":"21","author":"Kunimasa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.114831_b0290","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.addr.2023.114831_b0295","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.addr.2023.114831_b0300","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2023.114831_b0305","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41590-021-01121-x","article-title":"The immunoregulatory landscape of human tuberculosis granulomas","volume":"23","author":"McCaffrey","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00303","article-title":"The Rise of Non-Tuberculosis Mycobacterial Lung Disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0315","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114831_b0320","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0325","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114831_b0330","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cell.2020.08.025","article-title":"Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19","volume":"183","author":"Kaneko","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114831_b0335","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2023.114831_b0340","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm.2754","article-title":"Therapies for allergic inflammation: refining strategies to induce tolerance","volume":"18","author":"Akdis","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2023.114831_b0345","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2174\/1568009615666150602143751","article-title":"Aerosol Delivery in the Treatment of Lung Cancer","volume":"15","author":"Storti","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.addr.2023.114831_b0350","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12951-022-01307-x","article-title":"A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases","volume":"20","author":"He","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.114831_b0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114831_b0360","doi-asserted-by":"crossref","unstructured":"P. Muralidharan, M. Malapit, E. Mallory, D. Hayes, Jr., H.M. Mansour, Inhalable nanoparticulate powders for respiratory delivery, Nanomedicine: NBM, 11 (2015) 1189-1199.","DOI":"10.1016\/j.nano.2015.01.007"},{"key":"10.1016\/j.addr.2023.114831_b0365","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000367852","article-title":"Targeting inhaled therapy beyond the lungs","volume":"88","author":"Mortensen","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.addr.2023.114831_b0370","series-title":"Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles","author":"Hinds","year":"1999"},{"key":"10.1016\/j.addr.2023.114831_b0375","series-title":"Principles of pulmonary medicine","author":"Weinberger","year":"2008"},{"key":"10.1016\/j.addr.2023.114831_b0380","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/aic.690480102","article-title":"Delivery of Biological Agents by Aerosols","volume":"48","author":"Edwards","year":"2002","journal-title":"AIChE J"},{"key":"10.1016\/j.addr.2023.114831_b0385","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.4155\/tde-2017-0093","article-title":"Pulmonary aerosol delivery and the importance of growth dynamics","volume":"8","author":"Haddrell","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0390","doi-asserted-by":"crossref","first-page":"152S","DOI":"10.1378\/chest.88.2_Supplement.152S","article-title":"Aerosol Deposition Considerations in Inhalation Therapy","volume":"88","author":"Newman","year":"1985","journal-title":"Chest"},{"key":"10.1016\/j.addr.2023.114831_b0395","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/08958370304468","article-title":"Ultrafine Particle Deposition in Humans During Rest and Exercise","volume":"15","author":"Daigle","year":"2003","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.addr.2023.114831_b0400","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/jamp.2014.1189","article-title":"Effect of Posture on Regional Deposition of Coarse Particles in the Healthy Human Lung","volume":"28","author":"S\u00e1","year":"2015","journal-title":"J Aerosol Med Pulm Deliv"},{"key":"10.1016\/j.addr.2023.114831_b0405","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/jphp.12541","article-title":"The function and performance of aqueous aerosol devices for inhalation therapy","volume":"68","author":"Carvalho","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2023.114831_b0410","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.126.5.1619","article-title":"Comparison of Breath-Enhanced to Breath-Actuated Nebulizers for Rate, Consistency, and Efficiency","volume":"126","author":"Leung","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.addr.2023.114831_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/ejp.2014.00087","article-title":"Ultrasonic, and Mesh Nebulizers: An Evaluation of Nebulizers for Better Clinical Outcomes","volume":"16","author":"Ari","year":"2014","journal-title":"Eurasian Journal of Pulmonology"},{"key":"10.1016\/j.addr.2023.114831_b0420","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1081\/DDC-100107320","article-title":"Study of the Technological Parameters of Ultrasonic Nebulization","volume":"27","author":"Flament","year":"2001","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b0425","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1183\/18106838.0203.252","article-title":"The mesh nebuliser: a recent technical innovation for aerosol delivery","volume":"2","author":"Vecellio","year":"2006","journal-title":"Breathe"},{"key":"10.1016\/j.addr.2023.114831_b0430","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(10)60926-9","article-title":"Aerosol drug delivery: developments in device design and clinical use","volume":"377","author":"Dolovich","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114831_b0435","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1208\/s12249-013-0062-y","article-title":"Advances in metered dose inhaler technology: hardware development","volume":"15","author":"Stein","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.114831_b0440","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1208\/s12249-013-0063-x","article-title":"Advances in metered dose inhaler technology: formulation development","volume":"15","author":"Myrdal","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.114831_b0445","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1208\/s12249-015-0317-x","article-title":"Devices for dry powder drug delivery to the lung","volume":"16","author":"Berkenfeld","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.114831_b0450","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s12325-019-01066-6","article-title":"Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes","volume":"36","author":"Levy","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.addr.2023.114831_b0455","doi-asserted-by":"crossref","unstructured":"A. Haywood, B.D. Glass, - Pharmaceutical excipients \u2013 where do we begin?, - 34 (2011) - 114.","DOI":"10.18773\/austprescr.2011.060"},{"key":"10.1016\/j.addr.2023.114831_b0460","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijpharm.2018.04.034","article-title":"Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation","volume":"544","author":"Shetty","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.addr.2023.114831_b0465","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0939-6411(03)00044-4","article-title":"Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein","volume":"56","author":"Steckel","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.114831_b0470","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4161\/mabs.29938","article-title":"Effect of formulation on the stability and aerosol performance of a nebulized antibody","volume":"6","author":"Respaud","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2023.114831_b0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/jam.1994.7.89","article-title":"Generation of Aerosolized Drugs","volume":"7","author":"Wolff","year":"1994","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.addr.2023.114831_b0480","unstructured":"K.K. Mythri .G, M. Rupesh Kumar,Sd. Jagadeesh Singh, Novel Mucoadhesive Polymers - A Review, ssue : 8."},{"key":"10.1016\/j.addr.2023.114831_b0485","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.addr.2011.05.003","article-title":"Lactose characteristics and the generation of the aerosol","volume":"64","author":"Pilcer","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0490","article-title":"Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates","author":"Yoshida","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.114831_b0495","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/089426803772455622","article-title":"Cascade Impactors for the Size Characterization of Aerosols from Medical Inhalers: Their Uses and Limitations","volume":"16","author":"Mitchell","year":"2003","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.addr.2023.114831_b0500","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s11095-021-03082-0","article-title":"Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers","volume":"38","author":"Tavernini","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114831_b0505","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/jamp.2019.1564","article-title":"Realizing Lobe-Specific Aerosol Targeting in a 3D-Printed In Vitro Lung Model","volume":"34","author":"Kolewe","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0510","doi-asserted-by":"crossref","first-page":"S-71-S-87","DOI":"10.1089\/jamp.2010.0836","article-title":"The Particle has Landed\u2014Characterizing the Fate of Inhaled Pharmaceuticals","volume":"23","author":"Patton","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0515","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/17425247.2019.1551875","article-title":"Use of computational fluid dynamics deposition modeling in respiratory drug delivery","volume":"16","author":"Longest","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0520","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ejps.2013.06.004","article-title":"In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals","volume":"49","author":"Nahar","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.addr.2023.114831_b0525","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jaerosci.2011.06.005","article-title":"In-vitro cell exposure studies for the assessment of nanoparticle toxicity in the lung\u2014A dialog between aerosol science and biology","volume":"42","author":"Paur","year":"2011","journal-title":"J Aerosol Sci"},{"key":"10.1016\/j.addr.2023.114831_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106337","article-title":"Human lung cell models to study aerosol delivery \u2013 considerations for model design and development","volume":"180","author":"Rothen-Rutishauser","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.114831_b0535","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/17425247.2020.1730807","article-title":"Innovative preclinical models for pulmonary drug delivery research","volume":"17","author":"Ehrmann","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2023.114831_b0540","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1039\/D2BM00828A","article-title":"Destructive fibrotic teamwork: how both microenvironment stiffness and profibrotic interleukin 13 impair alveolar macrophage phenotype and function","volume":"10","author":"Bomb","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2023.114831_b0545","doi-asserted-by":"crossref","DOI":"10.1063\/1.5023034","article-title":"Biomimetics of the pulmonary environment in vitro: A microfluidics perspective","volume":"12","author":"Tenenbaum-Katan","year":"2018","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.addr.2023.114831_b0550","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.1188302","article-title":"Ingber, Reconstituting Organ-Level Lung Functions on a Chip","volume":"328","author":"Huh","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114831_b0555","doi-asserted-by":"crossref","first-page":"L167","DOI":"10.1152\/ajplung.1999.277.1.L167","article-title":"Stretch induces cytokine release by alveolar epithelial cells in vitro","volume":"277","author":"Vlahakis","year":"1999","journal-title":"Am J Physiol-Lung C"},{"key":"10.1016\/j.addr.2023.114831_b0560","doi-asserted-by":"crossref","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINS","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"key":"10.1016\/j.addr.2023.114831_b0565","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2015.08.011","article-title":"BALB\/c and C57BL\/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity","volume":"43","author":"Fransen","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2023.114831_b0570","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00011-009-0054-2","article-title":"Mouse models of asthma: a comparison between C57BL\/6 and BALB\/c strains regarding bronchial responsiveness, inflammation, and cytokine production","volume":"58","author":"Gueders","year":"2009","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.addr.2023.114831_b0575","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000199715","article-title":"Comparison of Acute Inflammatory and Chronic Structural Asthma-Like Responses between C57BL\/6 and BALB\/c Mice","volume":"149","author":"Van Hove","year":"2009","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0580","article-title":"Respiratory Tract Deposition and Distribution Pattern of Microparticles in Mice Using Different Pulmonary Delivery Techniques","volume":"6","author":"Kunda","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2023.114831_b0585","series-title":"Lung Innate Immunity and Inflammation: Methods and Protocols","first-page":"415","article-title":"Delivery of Therapeutics to the Lung","author":"Price","year":"2018"},{"key":"10.1016\/j.addr.2023.114831_b0590","doi-asserted-by":"crossref","unstructured":"H. Pan, G.H. Deutsch, S.E. Wert, N. Ambalavanan, C. Ansong, M.E. Ardini-Poleske, J. Bagwell, C. Chan, C. Frevert, D. Gabriel, J.S. Hagood, C.B. Hill, J. Holden-Wiltse, A.G. Jegga, T.J. Mariani, A.M. Masci, W. Shi, D. Warburton, K. A, S. On behalf of the Ontology, N.M.A.o.L.D.P. Consortium, Comprehensive anatomic ontologies for lung development: A comparison of alveolar formation and maturation within mouse and human lung, Journal of Biomedical Semantics, 10 (2019) 18.","DOI":"10.1186\/s13326-019-0209-1"},{"key":"10.1016\/j.addr.2023.114831_b0595","doi-asserted-by":"crossref","first-page":"S-39-S-57","DOI":"10.1089\/jamp.2010.0839","article-title":"Deposition, Imaging, and Clearance: What Remains to be Done?","volume":"23","author":"Scheuch","year":"2010","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114641","article-title":"Imaging drug delivery to the lungs: Methods and applications in oncology","volume":"192","author":"Man","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0605","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/rccm.200410-1414OC","article-title":"Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size","volume":"172","author":"Usmani","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.addr.2023.114831_b0610","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jpc.15909","article-title":"Controlled inhalation improves central and peripheral deposition in cystic fibrosis patients with moderate lung disease","volume":"58","author":"Bourke","year":"2022","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.addr.2023.114831_b0615","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-0716-1001-5_15","article-title":"Cellular and Biochemical Analysis of Bronchoalveolar Lavage Fluid from Murine Lungs","volume":"2223","author":"Kalidhindi","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.addr.2023.114831_b0620","series-title":"Bronchoalveolar Lavage, StatPearls, StatPearls Publishing Copyright \u00a9 2022","author":"Patel","year":"2022"},{"key":"10.1016\/j.addr.2023.114831_b0625","article-title":"Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery","volume":"21","author":"Li","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.addr.2023.114831_b0630","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003428.pub2","article-title":"Inhaled bronchodilators for cystic fibrosis","author":"Halfhide","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0635","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1183\/20734735.014813","article-title":"Long-acting bronchodilators in COPD: where are we now and where are we going?","volume":"10","author":"Cazzola","year":"2014","journal-title":"Breathe"},{"key":"10.1016\/j.addr.2023.114831_b0640","doi-asserted-by":"crossref","unstructured":"S. Smith, C.T. Edwards, Long-acting inhaled bronchodilators for cystic fibrosis, Cochrane Database Syst Rev, 12 (2017) Cd012102.","DOI":"10.1002\/14651858.CD012102"},{"key":"10.1016\/j.addr.2023.114831_b0645","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.addr.2023.114831_b0650","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.201609-1794CI","article-title":"How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?","volume":"196","author":"Beeh","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.addr.2023.114831_b0655","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1465-9921-9-3","article-title":"(R)-albuterol decreases immune responses: role of activated T cells","volume":"9","author":"Ferrada","year":"2008","journal-title":"Respir Res"},{"key":"10.1016\/j.addr.2023.114831_b0660","first-page":"33","article-title":"The development of anticholinergics in the management of COPD","volume":"2","author":"Scullion","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.addr.2023.114831_b0665","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical Pharmacology of Corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir. Care"},{"key":"10.1016\/j.addr.2023.114831_b0670","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40413-016-0117-0","article-title":"The use of inhaled corticosteroids in pediatric asthma: update","volume":"9","author":"Hossny","year":"2016","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.addr.2023.114831_b0675","article-title":"Combination Therapy with Budesonide and Formoterol in Single Inhaler of Asthma","volume":"2","author":"Hamzavi","year":"2010","journal-title":"Clinical Medicine Insights: Therapeutics"},{"key":"10.1016\/j.addr.2023.114831_b0680","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1874306401408010059","article-title":"Systemic effects of inhaled corticosteroids: an overview","volume":"8","author":"Pandya","year":"2014","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.addr.2023.114831_b0685","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pupt.2014.10.006","article-title":"Differences in the efficacy and safety among inhaled corticosteroids (ICS)\/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS","volume":"30","author":"Latorre","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.addr.2023.114831_b0690","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.2147\/COPD.S286149","article-title":"Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study","volume":"15","author":"Lee","year":"2020","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.addr.2023.114831_b0695","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pupt.2015.04.001","article-title":"The risk and outcomes of pneumonia in patients on inhaled corticosteroids","volume":"32","author":"Sibila","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b0700","first-page":"1257","article-title":"Leukotriene modifiers in the treatment of asthma","volume":"316","author":"Sampson","year":"1998","journal-title":"Look promising across the board of asthma severity, Bmj"},{"key":"10.1016\/j.addr.2023.114831_b0705","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2222.2006.02498.x","article-title":"Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis","volume":"36","author":"Peters-Golden","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.addr.2023.114831_b0710","doi-asserted-by":"crossref","unstructured":"A. Di Gennaro, J.Z. Haeggstr\u00f6m, Chapter Two - The Leukotrienes: Immune-Modulating Lipid Mediators of Disease, in: F.W. Alt (Ed.) Advances in Immunology, Academic Press2012, pp. 51-92.","DOI":"10.1016\/B978-0-12-394300-2.00002-8"},{"key":"10.1016\/j.addr.2023.114831_b0735","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CRD.0000000000000143","article-title":"Inhaled insulin","volume":"25","author":"Chan","year":"2017","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0740","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0169-409X(98)00074-X","article-title":"Inhaled insulin","volume":"35","author":"Patton","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0745","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4155\/tde.10.45","article-title":"Interview: Interview with John Patton","volume":"1","author":"Patton","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0750","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2337\/diacare.6.4.374","article-title":"Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus","volume":"6","author":"Dimitriadis","year":"1983","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.114831_b0755","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0889-8529(05)70269-3","article-title":"Novel forms of insulin delivery","volume":"26","author":"Saudek","year":"1997","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.addr.2023.114831_b0760","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3949\/ccjm.66.5.293","article-title":"New insulin replacement technologies: overcoming barriers to tight glycemic control","volume":"66","author":"Leslie","year":"1999","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.addr.2023.114831_b0765","unstructured":"J. Skyler, R. Gelfand, I. Kourides, Treatment of type 1 diabetes mellitus with inhaled human insulin: a 3-month, multicenter trial, Diabetes, AMER DIABETES ASSOC 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA, 1998, pp. A61-A61."},{"key":"10.1016\/j.addr.2023.114831_b0770","doi-asserted-by":"crossref","unstructured":"W.T. Cefalu, J.S. Skyler, I.A. Kourides, W.H. Landschulz, C.C. Balagtas, S.-L. Cheng, R.A. Gelfand, I.I.S. Group*, Inhaled human insulin treatment in patients with type 2 diabetes mellitus, Annals of internal medicine, 134 (2001) 203-207.","DOI":"10.7326\/0003-4819-134-3-200102060-00011"},{"key":"10.1016\/j.addr.2023.114831_b0775","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","article-title":"Commentary: Why Was Inhaled Insulin a Failure in the Market?","volume":"29","author":"Oleck","year":"2016","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.addr.2023.114831_b0780","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/biomedicines10061440","article-title":"Harnessing the Potential of Enzymes as Inhaled Therapeutics in Respiratory Tract Diseases: A Review of the Literature","volume":"10","author":"Vanderstocken","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2023.114831_b0785","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/jps.24353","article-title":"Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration","volume":"104","author":"Mcleod","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.114831_b0790","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.4049\/jimmunol.1800141","article-title":"Inhaled IL-10 suppresses lung tumorigenesis via abrogation of inflammatory macrophage\u2013th17 cell axis","volume":"201","author":"Li","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b0795","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","article-title":"Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system","volume":"196","author":"Guilleminault","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b0800","doi-asserted-by":"crossref","unstructured":"V. Herv\u00e9, N. Rabbe, L. Guilleminault, F. Paul, L. Schlick, N. Azzopardi, M. Duruisseaux, D. Fouquenet, J. Montharu, F. Redini, VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations, MAbs, Taylor & Francis, 2014, pp. 1638-1648.","DOI":"10.4161\/mabs.34454"},{"key":"10.1016\/j.addr.2023.114831_b0805","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijpharm.2018.07.054","article-title":"Dosing considerations for inhaled biologics","volume":"549","author":"Ferrati","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b0810","doi-asserted-by":"crossref","first-page":"1940650","DOI":"10.1080\/21645515.2021.1940650","article-title":"Inhaled antibodies: Quality and performance considerations","volume":"18","author":"Hickey","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.addr.2023.114831_b0815","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0192623320946297","article-title":"Perspectives on lung dose and inhaled biomolecules","volume":"49","author":"Wolff","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2023.114831_b0820","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2023.114831_b0825","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2017.11.001","article-title":"Mucus models to evaluate the diffusion of drugs and particles","volume":"124","author":"Lock","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0830","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejpb.2021.04.003","article-title":"Oral inhalation for delivery of proteins and peptides to the lungs","volume":"163","author":"Fr\u00f6hlich","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.114831_b0835","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2014.05.021","article-title":"PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract","volume":"187","author":"Koussoroplis","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b0840","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2023.114831_b0845","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00506-1","article-title":"Preparation of peptide and protein powders for inhalation","volume":"26","author":"Johnson","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0850","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/941243","article-title":"Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications","volume":"2012","author":"Garcia","year":"2012","journal-title":"Journal of Drug Delivery"},{"key":"10.1016\/j.addr.2023.114831_b0855","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1021\/acs.molpharmaceut.6b00066","article-title":"Pulmonary Delivery of Butyrylcholinesterase as a Model Protein to the Lung","volume":"13","author":"Rahhal","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b0860","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.addr.2006.07.014","article-title":"Inhaled cytokines and cytokine antagonists","volume":"58","author":"Thipphawong","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b0865","first-page":"37","article-title":"Inhaled Interferon and diffusion capacity in idiopathic pulmonary fibrosis (IPF)","volume":"32","author":"Skaria","year":"2015","journal-title":"Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG"},{"key":"10.1016\/j.addr.2023.114831_b0870","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jamp.2011.0919","article-title":"Delivery and safety of inhaled interferon-\u03b3 in idiopathic pulmonary fibrosis","volume":"25","author":"Diaz","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0875","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/00003246-200207000-00015","article-title":"Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-\u03b3","volume":"30","author":"Nakos","year":"2002","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.addr.2023.114831_b0880","doi-asserted-by":"crossref","first-page":"S1740","DOI":"10.21037\/jtd.2019.04.62","article-title":"Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)","volume":"11","author":"Saito","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.addr.2023.114831_b0885","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1089\/jamp.2015.1221","article-title":"Pulmonary fibrosis treated with inhaled interferon-gamma (IFN-\u03b3)","volume":"28","author":"Fusiak","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b0890","doi-asserted-by":"crossref","unstructured":"A.K. Abbas, E. Trotta, D. R. Simeonov, A. Marson, J.A. Bluestone, Revisiting IL-2: Biology and therapeutic prospects, Science immunology, 3 (2018) eaat1482.","DOI":"10.1126\/sciimmunol.aat1482"},{"key":"10.1016\/j.addr.2023.114831_b0895","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/annonc\/mdh137","article-title":"Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2","volume":"15","author":"Merimsky","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2023.114831_b0900","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1442-2042.1997.tb00205.x","article-title":"Inhalation of lnterleukin-2 Combined with Subcutaneous Administration of Interferon for the Treatment of Pulmonary Metastases from Renal Cell Carcinoma","volume":"4","author":"Nakamoto","year":"1997","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.addr.2023.114831_b0905","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2017.11.002","article-title":"Oligonucleotide therapies for the lung: ready to return to the clinic?","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b0910","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tips.2020.08.002","article-title":"Inhaled RNA therapy: from promise to reality","volume":"41","author":"Chow","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2023.114831_b0915","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","article-title":"RNA therapy: current status and future potential","volume":"56","author":"Kim","year":"2020","journal-title":"Chonnam Med. J."},{"key":"10.1016\/j.addr.2023.114831_b0920","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tips.2020.04.007","article-title":"Therapeutic RNA strategies for chronic obstructive pulmonary disease","volume":"41","author":"Mei","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2023.114831_b0925","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/mtna.2011.1","article-title":"Oligonucleotide delivery to the lung: waiting to inhale","volume":"1","author":"Kjems","year":"2012","journal-title":"Molecular therapy. Nucleic acids"},{"key":"10.1016\/j.addr.2023.114831_b0930","doi-asserted-by":"crossref","unstructured":"J.V. Fahy, D.W. Cockcroft, L.-P. Boulet, H.H. Wong, F. Deschesnes, E.E. Davis, J. RUPPEL, J.Q. Su, D.C. Adelman, Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects, American journal of respiratory and critical care medicine, 160 (1999) 1023-1027.","DOI":"10.1164\/ajrccm.160.3.9810012"},{"key":"10.1016\/j.addr.2023.114831_b0935","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2023.114831_b0940","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.omtn.2019.02.013","article-title":"Intratracheal administration of siRNA triggers mRNA silencing in the lung to modulate T cell immune response and lung inflammation","volume":"16","author":"Ng","year":"2019","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.addr.2023.114831_b0945","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-18-0729","article-title":"Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4+ and CD8+ T-cell interplay","volume":"78","author":"Gallotta","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2023.114831_b0950","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/mt.2011.206","article-title":"Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense","volume":"19","author":"Moschos","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b0955","first-page":"987","article-title":"miRNA nanotherapeutics: potential and challenges in respiratory disorders","author":"Mehta","year":"2020","journal-title":"Future Science"},{"key":"10.1016\/j.addr.2023.114831_b0960","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1208\/s12249-018-1183-0","article-title":"Nucleic acid-based therapeutics for pulmonary diseases","volume":"19","author":"Chen","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.114831_b0965","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","article-title":"Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme","volume":"372","author":"Krug","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2023.114831_b0970","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1513\/pats.200701-019AW","article-title":"CpG DNA and immunomodulation of asthma","volume":"4","author":"Kline","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.addr.2023.114831_b0975","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cpt.938","article-title":"First-in-human study with the inhaled TLR9 oligonucleotide agonist AZD1419 results in interferon responses in the lung, and is safe and well-tolerated","volume":"104","author":"Jackson","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109015","article-title":"LncRNA MIR155HG regulates M1\/M2 macrophage polarization in chronic obstructive pulmonary disease","volume":"117","author":"Li","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2023.114831_b0985","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review","volume":"13","author":"Singh","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.114831_b0990","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/mp.53.3.111","article-title":"Monoclonal antibodies","volume":"53","author":"Nelson","year":"2000","journal-title":"Molecular pathology: MP"},{"key":"10.1016\/j.addr.2023.114831_b0995","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics12111025","article-title":"Pulmonary delivery of biological drugs","volume":"12","author":"Liang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114831_b1000","first-page":"1","article-title":"Inhaled protein\/peptide-based therapies for respiratory disease, Molecular and Cellular","volume":"3","author":"Fellner","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.addr.2023.114831_b1005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1165\/rcmb.2012-0031OC","article-title":"Nebulized Anti\u2013IL-13 Monoclonal Antibody Fab\u2032 Fragment Reduces Allergen-Induced Asthma","volume":"47","author":"Hacha","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.addr.2023.114831_b1010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2018.07.035","article-title":"Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942","volume":"35","author":"Burgess","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2023.114831_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103184","article-title":"Pulmonary vaccine delivery: An emerging strategy for vaccination and immunotherapy","volume":"69","author":"Masjedi","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2023.114831_b1020","doi-asserted-by":"crossref","DOI":"10.3390\/polym14204450","article-title":"Polymeric Nanoparticles for Inhaled Vaccines","author":"Al-Nemrawi","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2023.114831_b1025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle Vaccines Against Infectious Diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1030","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.10.061","article-title":"Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery","volume":"352","author":"Wang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b1035","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1039\/D1NR06512B","article-title":"Pulmonary delivery of mucosal nanovaccines","volume":"14","author":"Tang","year":"2022","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2023.114831_b1040","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","article-title":"Nanotechnology approaches for inhalation treatment of lung diseases","volume":"219","author":"Kuzmov","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b1045","first-page":"1","article-title":"Nanoparticles development for pulmonary vaccination: Challenges and opportunities","volume":"8","author":"Ghobadi","year":"2021","journal-title":"Nanomedicine Journal"},{"key":"10.1016\/j.addr.2023.114831_b1050","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.4049\/jimmunol.1203131","article-title":"Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints","volume":"191","author":"Hardy","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1055","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1021\/acsnano.9b03019","article-title":"Age-Dependent Translocation of Gold Nanoparticles across the Air-Blood Barrier","volume":"13","author":"Tsuda","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.114831_b1060","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1021\/acsnano.6b08551","article-title":"Inhaled Nanoparticles Accumulate at Sites of Vascular Disease","volume":"11","author":"Miller","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.114831_b1065","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1016\/j.vaccine.2012.10.050","article-title":"Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization","volume":"30","author":"Stano","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1070","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s11095-009-9894-2","article-title":"Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery","volume":"26","author":"Sung","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114831_b1075","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large Porous Particles for Pulmonary Drug Delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114831_b1080","first-page":"1590","article-title":"Factors affecting the deposition of inhaled porous drug particles","volume":"2002","author":"Musante","year":"2002","journal-title":"J Pharm Sci, Wiley-Liss Inc. and the American Pharmaceutical Association J Pharm Sci 91:1590\u20131600, 2002 United States"},{"key":"10.1016\/j.addr.2023.114831_b1085","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejpb.2010.12.002","article-title":"Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation","volume":"78","author":"Lebhardt","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.addr.2023.114831_b1090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jconrel.2011.10.030","article-title":"Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery","volume":"158","author":"Beck-Broichsitter","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2023.114831_b1095","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1002\/jps.22003","article-title":"Swellable microparticles as carriers for sustained pulmonary drug delivery","volume":"99","author":"El-Sherbiny","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.addr.2023.114831_b1100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/mp200351y","article-title":"Controlled Release Pulmonary Administration of Curcumin Using Swellable Biocompatible Microparticles","volume":"9","author":"El-Sherbiny","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1105","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1073\/pnas.1422923112","article-title":"Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization","volume":"112","author":"Fromen","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2023.114831_b1110","first-page":"677","article-title":"Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells, Nanomedicine: Nanotechnology","volume":"12","author":"Fromen","year":"2016","journal-title":"Biology and Medicine"},{"key":"10.1016\/j.addr.2023.114831_b1115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/acsnano.6b06061","article-title":"Aerosol Delivery of Functionalized Gold Nanoparticles Target and Activate Dendritic Cells in a 3D Lung Cellular Model","volume":"11","author":"Fytianos","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.114831_b1120","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles","volume":"7","author":"Fr\u00f6hlich","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.addr.2023.114831_b1125","unstructured":"A. Henning, N. Schneider M Fau - Nafee, L. Nafee N Fau - Muijs, E. Muijs L Fau - Rytting, X. Rytting E Fau - Wang, T. Wang X Fau - Kissel, D. Kissel T Fau - Grafahrend, D. Grafahrend D Fau - Klee, C.-M. Klee D Fau - Lehr, C.M. Lehr, Influence of particle size and material properties on mucociliary clearance from the airways."},{"key":"10.1016\/j.addr.2023.114831_b1130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2231-4040.90876","article-title":"A review on mucoadhesive polymer used in nasal drug delivery system","volume":"2","author":"Chaturvedi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.addr.2023.114831_b1135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/mp100255c","article-title":"Aerosolized PLA and PLGA Nanoparticles Enhance Humoral, Mucosal and Cytokine Responses to Hepatitis B Vaccine","volume":"8","author":"Thomas","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2023.114831_b1145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.114831_b1150","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2023.114831_b1155","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1007\/s11095-015-1701-7","article-title":"Distribution and Cellular Uptake of PEGylated PolymericParticles in the Lung Towards Cell-Specific Targeted Delivery","volume":"32","author":"Shen","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114831_b1160","doi-asserted-by":"crossref","unstructured":"L.T. Ferguson, X. Ma, J.W. Myerson, J. Wu, P.M. Glassman, M.E. Zamora, E.D. Hood, M. Zaleski, M. Shen, E.-O. Essien, V.V. Shuvaev, J.S. Brenner, Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases, Advanced NanoBiomed Research, n\/a (2023) 2200106.","DOI":"10.1002\/anbr.202200106"},{"key":"10.1016\/j.addr.2023.114831_b1165","doi-asserted-by":"crossref","unstructured":"R. Guagliardo, J. P\u00e9rez-Gil, S. De Smedt, K. Raemdonck, Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins, J Control Release, \u00a9 2018 Elsevier B.V, Netherlands, 2018, pp. 116-126.","DOI":"10.1016\/j.jconrel.2018.10.012"},{"key":"10.1016\/j.addr.2023.114831_b1170","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbamem.2017.04.019","article-title":"Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications, Biochimica et Biophysica Acta (BBA) -","volume":"1859","author":"Hidalgo","year":"2017","journal-title":"Biomembranes"},{"key":"10.1016\/j.addr.2023.114831_b1175","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425247.2015.1039509","article-title":"Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages","volume":"12","author":"Lee","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2023.114831_b1180","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11095-012-0891-5","article-title":"Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery","volume":"30","author":"Kunda","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114831_b1185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41565-020-00810-2","article-title":"Inducing immune tolerance with dendritic cell-targeting nanomedicines","volume":"16","author":"Cifuentes-Rius","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1190","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119806","article-title":"T helper type 1 biased immune responses by PPE17 loaded core-shell alginate-chitosan nanoparticles after subcutaneous and intranasal administration","volume":"282","author":"Najafi","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2023.114831_b1200","doi-asserted-by":"crossref","first-page":"2007557","DOI":"10.1002\/adma.202007557","article-title":"Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis","volume":"33","author":"Jin","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2023.114831_b1205","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1007\/s10904-020-01572-z","article-title":"Aluminum Nanoparticles Acting as a Pulmonary Vaccine Adjuvant-Delivery System (VADS) Able to Safely Elicit Robust Systemic and Mucosal Immunity","volume":"30","author":"Wang","year":"2020","journal-title":"J Inorg Organomet Polym Mater"},{"key":"10.1016\/j.addr.2023.114831_b1210","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/smll.201101059","article-title":"Fate and Toxicity of Metallic and Metal-Containing Nanoparticles for Biomedical Applications","volume":"7","author":"Li","year":"2011","journal-title":"Small"},{"key":"10.1016\/j.addr.2023.114831_b1215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/ntrev-2019-0017","article-title":"Toxicity of metallic nanoparticles in the central nervous system","volume":"8","author":"Sawicki","year":"2019","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.addr.2023.114831_b1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2020.101529","article-title":"Albumin nanocarriers for pulmonary drug delivery: An attractive approach","volume":"56","author":"Joshi","year":"2020","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2023.114831_b1225","first-page":"603","article-title":"Nanoparticles for mucosal vaccine delivery, Nanoengineered Biomaterials for Advanced","author":"Thakur","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b1230","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijbiomac.2021.12.129","article-title":"Recent advances on chitosan as an adjuvant for vaccine delivery","volume":"200","author":"Dmour","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2023.114831_b1235","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/btpr.10","article-title":"Biomaterials as vaccine adjuvants","volume":"24","author":"Jones","year":"2008","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.addr.2023.114831_b1240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1006\/mthe.1999.0021","article-title":"Aerosol Delivery of Robust Polyethyleneimine\u2013 DNA Complexes for Gene Therapy and Genetic Immunization","volume":"1","author":"Densmore","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1245","doi-asserted-by":"crossref","unstructured":"A. Suberi, M.K. Grun, T. Mao, B. Israelow, M. Reschke, J. Grundler, L. Akhtar, T. Lee, K. Shin, A.S. Piotrowski-Daspit, R.J. Homer, A. Iwasaki, H.W. Suh, W.M. Saltzman, Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccination, bioRxiv, (2022) 2022.2003.2022.485401.","DOI":"10.1101\/2022.03.22.485401"},{"key":"10.1016\/j.addr.2023.114831_b1250","doi-asserted-by":"crossref","first-page":"1805116","DOI":"10.1002\/adma.201805116","article-title":"Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2023.114831_b1255","doi-asserted-by":"crossref","first-page":"e0137504","DOI":"10.1371\/journal.pone.0137504","article-title":"Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration","volume":"10","author":"Johler","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114831_b1260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2003.09.006","article-title":"Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice","volume":"57","author":"Vila","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.114831_b1265","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-3155-10-20","article-title":"Encapsulation of Alpha-1 antitrypsin in PLGA nanoparticles. In Vitro characterization as an effective aerosol formulation in pulmonary diseases","volume":"10","author":"Pirooznia","year":"2012","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1270","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092179","article-title":"Lipid Nanoparticles as Delivery Vehicles for Inhaled Therapeutics","volume":"10","author":"Leong","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2023.114831_b1275","first-page":"1059","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs, Nature","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Biomed. Eng."},{"key":"10.1016\/j.addr.2023.114831_b1280","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled Liposomal Antimicrobial Delivery in Lung Infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114831_b1285","first-page":"949","article-title":"Lipid nanoparticles for the inhalation of mRNA, Nature","volume":"5","author":"Chang","year":"2021","journal-title":"Biomed. Eng."},{"key":"10.1016\/j.addr.2023.114831_b1290","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.114831_b1295","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat Mater"},{"key":"10.1016\/j.addr.2023.114831_b1300","article-title":"Generation of Effector Memory T Cell-Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination","volume":"5","author":"Li Adrienne","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.114831_b1305","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.addr.2023.114831_b1310","first-page":"29","article-title":"Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles","volume":"433","author":"Grego","year":"2021","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.addr.2023.114831_b1315","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1158\/0008-5472.CAN-04-0138","article-title":"Targeting Dendritic Cells with Antigen-Containing Liposomes: A Highly Effective Procedure for Induction of Antitumor Immunity and for Tumor Immunotherapy","volume":"64","author":"van Broekhoven","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2023.114831_b1320","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vetimm.2013.05.005","article-title":"Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines","volume":"158","author":"Watarai","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.addr.2023.114831_b1325","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s44222-022-00012-6","article-title":"Biomaterials for intranasal and inhaled vaccine delivery","volume":"1","author":"Cahn","year":"2023","journal-title":"Nature Reviews Bioengineering"},{"key":"10.1016\/j.addr.2023.114831_b1330","doi-asserted-by":"crossref","first-page":"e1586","DOI":"10.1002\/wnan.1586","article-title":"Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases","volume":"12","author":"Anderson","year":"2020","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.addr.2023.114831_b1335","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fbioe.2019.00406","article-title":"Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis","volume":"7","author":"Velino","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.addr.2023.114831_b1340","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/mi.2012.74","article-title":"The alveolar macrophages in asthma: a double-edged sword","volume":"5","author":"Balhara","year":"2012","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1345","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.addr.2015.10.020","article-title":"Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity","volume":"98","author":"Northrup","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b1350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864403","article-title":"Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases","volume":"13","author":"Benne","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1355","doi-asserted-by":"crossref","first-page":"516","DOI":"10.21037\/atm.2019.09.153","article-title":"Nanotechnology bring a new hope for asthmatics","volume":"7","author":"Cheng","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.addr.2023.114831_b1360","first-page":"L500","article-title":"Airway epithelial-targeted nanoparticles for asthma therapy, American Journal of Physiology-Lung Cellular and Molecular","volume":"318","author":"Kan","year":"2020","journal-title":"Physiology"},{"key":"10.1016\/j.addr.2023.114831_b1365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3858\/emm.2011.43.5.028","article-title":"Alveolar macrophages modulate allergic inflammation in a murine model of asthma","volume":"43","author":"Bang","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.addr.2023.114831_b1370","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.tiv.2008.05.008","article-title":"Cell types involved in allergic asthma and their use in in vitro models to assess respiratory sensitization","volume":"22","author":"Verstraelen","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.addr.2023.114831_b1375","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/eji.1830211128","article-title":"Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity","volume":"21","author":"Thepen","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.addr.2023.114831_b1380","doi-asserted-by":"crossref","unstructured":"C.B. Smarr, W.T. Yap, T.P. Neef, R.M. Pearson, Z.N. Hunter, I. Ifergan, D.R. Getts, P.J. Bryce, L.D. Shea, S.D. Miller, Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre-and postsensitization, Proceedings of the National Academy of Sciences, 113 (2016) 5059-5064.","DOI":"10.1073\/pnas.1505782113"},{"key":"10.1016\/j.addr.2023.114831_b1385","doi-asserted-by":"crossref","first-page":"5058121","DOI":"10.1155\/2022\/5058121","article-title":"Targeting COPD with PLGA-Based Nanoparticles: Current Status and Prospects","volume":"2022","author":"Saxena","year":"2022","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.addr.2023.114831_b1390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2019.01.002","article-title":"Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease","volume":"136","author":"Mohamed","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.114831_b1395","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1743-8977-10-19","article-title":"Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease","volume":"10","author":"Geiser","year":"2013","journal-title":"Part Fibre Toxicol"},{"key":"10.1016\/j.addr.2023.114831_b1400","article-title":"Inhaled chemotherapy adverse effects: mechanisms and protection methods","volume":"8","author":"Sardeli","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.addr.2023.114831_b1405","first-page":"55","article-title":"Nanotechnology-based inhalation treatments for lung cancer: state of the art","volume":"8","author":"Ahmad","year":"2015","journal-title":"Nanotechnol Sci Appl"},{"key":"10.1016\/j.addr.2023.114831_b1410","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12951-022-01489-4","article-title":"Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy","volume":"20","author":"Li","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.addr.2023.114831_b1415","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2023.114831_b1420","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1021\/mp4000053","article-title":"Preventative Vaccine-Loaded Mannosylated Chitosan Nanoparticles Intended for Nasal Mucosal Delivery Enhance Immune Responses and Potent Tumor Immunity","volume":"10","author":"Yao","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1425","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","article-title":"An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114831_b1430","doi-asserted-by":"crossref","first-page":"18608","DOI":"10.1039\/D1NR05001J","article-title":"Combination of DNA demethylation and chemotherapy to trigger cell pyroptosis for inhalation treatment of lung cancer","volume":"13","author":"Xie","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2023.114831_b1435","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.apsb.2018.03.004","article-title":"Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.addr.2023.114831_b1440","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001022","article-title":"Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination","volume":"8","author":"Huang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.addr.2023.114831_b1445","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111937","article-title":"Artesunate-loaded porous PLGA microsphere as a pulmonary delivery system for the treatment of non-small cell lung cancer","volume":"206","author":"Xiong","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2023.114831_b1450","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s11671-018-2661-8","article-title":"Modified Fe3O4 Magnetic Nanoparticle Delivery of CpG Inhibits Tumor Growth and Spontaneous Pulmonary Metastases to Enhance Immunotherapy","volume":"13","author":"Zhang","year":"2018","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.addr.2023.114831_b1455","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/jamp.2018.1507","article-title":"Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis","volume":"33","author":"Khoo","year":"2019","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b1460","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101938","article-title":"Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis","volume":"63","author":"Surber","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11095-019-2732-2","article-title":"Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis","volume":"37","author":"Kaminskas","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114831_b1470","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1475","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2023.114831_b1480","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pupt.2016.01.001","article-title":"Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model","volume":"36","author":"Seo","year":"2016","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1485","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijpharm.2018.09.031","article-title":"Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles","volume":"551","author":"Hu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1490","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/23\/50\/505101","article-title":"Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice","volume":"23","author":"Trivedi","year":"2012","journal-title":"Nanotechnology"},{"key":"10.1016\/j.addr.2023.114831_b1495","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2018.01.012","article-title":"Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats","volume":"49","author":"Corboz","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1500","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejpb.2012.11.023","article-title":"Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2","volume":"84","author":"Ivanova","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.114831_b1505","article-title":"Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2023.114831_b1510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bbrc.2020.09.018","article-title":"Potent antiviral effect of silver nanoparticles on SARS-CoV-2","volume":"533","author":"Jeremiah","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.addr.2023.114831_b1515","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.addr.2023.114831_b1520","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.addr.2023.114831_b1525","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.addr.2023.114831_b1530","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)","volume":"198","author":"Griffith","year":"2018","journal-title":"A Prospective, Open-Label, Randomized Study, Am J Respir Crit Care Med"},{"key":"10.1016\/j.addr.2023.114831_b1535","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jcf.2021.05.013","article-title":"Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection","volume":"20","author":"Bilton","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.addr.2023.114831_b1540","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pbc.24438","article-title":"Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed\/progressive osteosarcoma metastatic to the lung","volume":"60","author":"Chou","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.addr.2023.114831_b1545","first-page":"1","article-title":"Inhaled vaccine delivery in the combat against respiratory viruses: A, overview of recent developments and implications for COVID-19","volume":"2021","author":"Heida","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2023.114831_b1550","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.apsb.2019.05.003","article-title":"Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination","volume":"9","author":"Tomar","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2023.114831_b1555","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.addr.2023.114831_b1560","first-page":"543","article-title":"An evaluation of influenza immunization: influence of route of administration and vaccine strain","volume":"41","author":"Waldman","year":"1969","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.addr.2023.114831_b1565","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/oxfordjournals.aje.a121170","article-title":"Influenza antibody response following aerosal administration of inactivated viruis","volume":"91","author":"Waldman","year":"1970","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.addr.2023.114831_b1570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-15-60","article-title":"Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization","volume":"15","author":"Rajapaksa","year":"2014","journal-title":"Respir. Res."},{"key":"10.1016\/j.addr.2023.114831_b1575","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1016\/j.vaccine.2007.10.035","article-title":"Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB\/c mice","volume":"25","author":"Amorij","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1580","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pvr.2017.03.004","article-title":"Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature","volume":"3","author":"Peabody","year":"2017","journal-title":"Papillomavirus Research"},{"key":"10.1016\/j.addr.2023.114831_b1585","doi-asserted-by":"crossref","first-page":"e71953","DOI":"10.1371\/journal.pone.0071953","article-title":"Enhanced Nasal Mucosal Delivery and Immunogenicity of Anti-Caries DNA Vaccine through Incorporation of Anionic Liposomes in Chitosan\/DNA Complexes","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114831_b1590","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(99)95140-1","article-title":"Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial","volume":"355","author":"Dilraj","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2023.114831_b1595","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","article-title":"Live Attenuated Influenza Vaccine (FluMist\u00ae; Fluenz\u2122) A Review of its Use in the Prevention of Seasonal Influenza in Children and Adults","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.114831_b1600","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1586\/14760584.2015.1078732","article-title":"Efficacy and effectiveness of live attenuated influenza vaccine in school-age children","volume":"14","author":"Coelingh","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2023.114831_b1605","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3949\/ccjm.70.9.801","article-title":"Demystifying FluMist, a new intranasal, live influenza vaccine","volume":"70","author":"Mossad","year":"2003","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.addr.2023.114831_b1610","first-page":"2","article-title":"Evolution, benefits, and shortcomings of vaccine management","volume":"13","author":"McCullers","year":"2007","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1615","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","article-title":"Modern subunit vaccines: development, components, and research opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.addr.2023.114831_b1620","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/03639045.2019.1583758","article-title":"Subunit-based mucosal vaccine delivery systems for pulmonary delivery-Are they feasible?","volume":"45","author":"Marasini","year":"2019","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1625","doi-asserted-by":"crossref","first-page":"e0005071","DOI":"10.1371\/journal.pntd.0005071","article-title":"Precisely molded nanoparticle displaying DENV-E proteins induces robust serotype-specific neutralizing antibody responses","volume":"10","author":"Metz","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.addr.2023.114831_b1630","first-page":"523","article-title":"Development of a nanoparticle-based influenza vaccine using the PRINT\u00ae technology, Nanomedicine: Nanotechnology","volume":"9","author":"Galloway","year":"2013","journal-title":"Biology and Medicine"},{"key":"10.1016\/j.addr.2023.114831_b1635","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/19\/45\/455103","article-title":"Rapid generation of protein aerosols and nanoparticles via surface acoustic wave atomization","volume":"19","author":"Alvarez","year":"2008","journal-title":"Nanotechnology"},{"key":"10.1016\/j.addr.2023.114831_b1640","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jamp.2014.1176","article-title":"Spray-dried influenza antigen with trehalose and leucine produces an aerosolizable powder vaccine formulation that induces strong systemic and mucosal immunity after pulmonary administration","volume":"28","author":"Sou","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b1645","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/v12050488","article-title":"Virus-like particles as an immunogenic platform for cancer vaccines","volume":"12","author":"Caldeira","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2023.114831_b1650","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like particle vaccines: immunology and formulation for clinical translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2023.114831_b1655","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2021.01.016","article-title":"Stability of lyophilized and spray dried vaccine formulations","volume":"171","author":"Preston","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.114831_b1660","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1002\/wnan.1579","article-title":"Virus-like particles for vaccination against cancer","volume":"12","author":"Mohsen","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1665","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3413\/Nukmed-0811-16-03","article-title":"SPECT\/CT study of bronchial deposition of inhaled particles","volume":"55","author":"Ilic","year":"2016","journal-title":"Nuklearmedizin-NuclearMedicine"},{"key":"10.1016\/j.addr.2023.114831_b1670","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nnano.2015.292","article-title":"In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer","volume":"11","author":"Lizotte","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1675","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1089\/10430340260185058","article-title":"Intranasal Gene Transfer by Chitosan\u2013DNA Nanospheres Protects BALB\/c Mice Against Acute Respiratory Syncytial Virus Infection","volume":"13","author":"Kumar","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114831_b1680","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.vaccine.2003.09.044","article-title":"Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis","volume":"22","author":"Bivas-Benita","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1685","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.vaccine.2006.02.024","article-title":"An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits","volume":"24","author":"Wimer-Mackin","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1690","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b1695","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2011.07.039","article-title":"Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis","volume":"29","author":"Ballester","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1700","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.vaccine.2010.11.010","article-title":"PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration","volume":"29","author":"Stano","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1705","doi-asserted-by":"crossref","unstructured":"C. Nembrini, A. Stano, K.Y. Dane, M. Ballester, A.J. van der Vlies, B.J. Marsland, M.A. Swartz, J.A. Hubbell, Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination, Proceedings of the National Academy of Sciences, 108 (2011) E989-E997.","DOI":"10.1073\/pnas.1104264108"},{"key":"10.1016\/j.addr.2023.114831_b1710","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1016\/j.vaccine.2009.04.033","article-title":"Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA\u2013PEI nanoparticles enhances T cell responses in a DNA prime\/protein boost vaccination regimen in mice","volume":"27","author":"Bivas-Benita","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1715","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1208\/s12248-010-9229-6","article-title":"Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses","volume":"12","author":"Muttil","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.addr.2023.114831_b1720","doi-asserted-by":"crossref","unstructured":"S. Dhakal, J. Hiremath, K. Bondra, Y.S. Lakshmanappa, D.L. Shyu, K. Ouyang, K.I. Kang, B. Binjawadagi, J. Goodman, K. Tabynov, S. Krakowka, B. Narasimhan, C.W. Lee, G.J. Renukaradhya, Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs, J Control Release, \u00a9 2017 Elsevier B.V, Netherlands, 2017, pp. 194-205.","DOI":"10.1016\/j.jconrel.2016.12.039"},{"key":"10.1016\/j.addr.2023.114831_b1725","doi-asserted-by":"crossref","first-page":"1902650","DOI":"10.1002\/advs.201902650","article-title":"Engineering of nebulized metal\u2013phenolic capsules for controlled pulmonary deposition","volume":"7","author":"Ju","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2023.114831_b1730","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/mco2.101","article-title":"Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges","volume":"2","author":"Xi","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.addr.2023.114831_b1735","article-title":"Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems","volume":"63","author":"Abdellatif","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.addr.2023.114831_b1740","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/17425247.2022.2131767","article-title":"Are inhaled mRNA vaccines safe and effective?","volume":"19","author":"Jansen","year":"2022","journal-title":"A review of preclinical studies, Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.addr.2023.114831_b1745","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.copbio.2021.10.017","article-title":"Inhalable mRNA vaccines for respiratory diseases: a roadmap","volume":"74","author":"Roh","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1750","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ijpharm.2015.09.034","article-title":"Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles","volume":"495","author":"Kunda","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1755","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/vim.2015.0144","article-title":"Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN","volume":"29","author":"Singh","year":"2016","journal-title":"Viral Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1760","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2016.12.039","article-title":"Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs","volume":"247","author":"Dhakal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b1765","doi-asserted-by":"crossref","first-page":"e0228463","DOI":"10.1371\/journal.pone.0228463","article-title":"Induction of systemic immunity through nasal-associated lymphoid tissue (NALT) of mice intranasally immunized with Brucella abortus malate dehydrogenase-loaded chitosan nanoparticles","volume":"15","author":"Shim","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114831_b1770","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1021\/acs.molpharmaceut.7b00826","article-title":"Enhancing Mucosal Immune Response of Newcastle Disease Virus DNA Vaccine Using N-2-Hydroxypropyl Trimethylammonium Chloride Chitosan and N, O-Carboxymethyl Chitosan Nanoparticles as Delivery Carrier","volume":"15","author":"Zhao","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.114831_b1775","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104061","article-title":"Comparison of immune responses in guinea pigs by intranasal delivery with different nanoparticles-loaded FMDV DNA vaccine","volume":"142","author":"Zheng","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.addr.2023.114831_b1780","doi-asserted-by":"crossref","first-page":"eaau0810","DOI":"10.1126\/science.aau0810","article-title":"Pulmonary surfactant\u2013biomimetic nanoparticles potentiate heterosubtypic influenza immunity","volume":"367","author":"Wang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114831_b1785","doi-asserted-by":"crossref","first-page":"10939","DOI":"10.1021\/acsnano.9b00326","article-title":"Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells","volume":"13","author":"Knight","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.114831_b1790","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-023-01782-w","article-title":"Aluminum-Based Metal-Organic Framework Nanoparticles as Pulmonary Vaccine Adjuvants","author":"Stillman","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1795","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-Based Vaccines Against Respiratory Viruses","volume":"10","author":"Al-Halifa","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1800","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tibtech.2010.12.009","article-title":"New developments in dry powder pulmonary vaccine delivery","volume":"29","author":"Sou","year":"2011","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.addr.2023.114831_b1805","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/17425247.4.6.651","article-title":"Design of nanoparticle-based dry powder pulmonary vaccines","volume":"4","author":"Pulliam","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.114831_b1810","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: Current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.addr.2023.114831_b1815","doi-asserted-by":"crossref","first-page":"e0139916","DOI":"10.1371\/journal.pone.0139916","article-title":"Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114831_b1820","doi-asserted-by":"crossref","first-page":"e1290036","DOI":"10.1080\/2162402X.2017.1290036","article-title":"Translational nanoparticle engineering for cancer vaccines","volume":"6","author":"Grippin","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2023.114831_b1825","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2015.09.069","article-title":"Shape and size-dependent immune response to antigen-carrying nanoparticles","volume":"220","author":"Kumar","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2023.114831_b1830","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","article-title":"Nanoparticle vaccines","volume":"32","author":"Zhao","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1835","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.addr.2023.114831_b1840","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.coph.2011.03.004","article-title":"TLR based therapeutics","volume":"11","author":"Dunne","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2023.114831_b1845","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2023.114831_b1850","series-title":"Mucosal Vaccines","first-page":"167","article-title":"Chapter 10 - Innate Immunity-Based Mucosal Modulators and Adjuvants","author":"Johnson-Weaver","year":"2020"},{"key":"10.1016\/j.addr.2023.114831_b1855","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/acscentsci.1c00200","article-title":"Bacterial Peptidoglycan Fragments Differentially Regulate Innate Immune Signaling","volume":"7","author":"Bersch","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.addr.2023.114831_b1860","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nbt955","article-title":"The ABCs of artificial antigen presentation","volume":"22","author":"Kim","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1865","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ymthe.2021.08.007","article-title":"IL-6-elafin genetically modified macrophages as a lung immunotherapeutic strategy against Pseudomonas aeruginosa infections","volume":"30","author":"Kheir","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1870","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009750","article-title":"Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis","volume":"6","author":"Happle","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.114831_b1875","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature13807","article-title":"Pulmonary macrophage transplantation therapy","volume":"514","author":"Suzuki","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114831_b1880","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","article-title":"Inhalable dry powder mRNA vaccines based on extracellular vesicles","volume":"5","author":"Popowski","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.addr.2023.114831_b1885","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2020.105009","article-title":"Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises","volume":"234","author":"Rezakhani","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.addr.2023.114831_b1890","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jconrel.2020.12.053","article-title":"Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation","volume":"330","author":"Kim","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114831_b1895","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.2147\/IJN.S166584","article-title":"Matrix metalloproteinase 2\/9-triggered-release micelles for inhaled drug delivery to treat lung cancer: preparation and in vitro\/in vivo studies","volume":"13","author":"Wang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.114831_b1900","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.3390\/ijms21176435","article-title":"State of the art review of cell therapy in the treatment of lung disease, and the potential for aerosol delivery","volume":"21","author":"Brave","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2023.114831_b1905","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/bit.20549","article-title":"Aerosol delivery of mammalian cells for tissue engineering","volume":"91","author":"Roberts","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2023.114831_b1910","first-page":"334","article-title":"Mammalian cell delivery via aerosol deposition","volume":"72","author":"Veazey","year":"2005","journal-title":"Journal of Biomedical Materials Research Part B: Applied Biomaterials: An Official Journal of The Society for Biomaterials The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials"},{"key":"10.1016\/j.addr.2023.114831_b1915","doi-asserted-by":"crossref","unstructured":"E. Kardia, N.S.S.A. Halim, B.H. Yahaya, Aerosol-based cell therapy for treatment of lung diseases, Stem Cell Heterogeneity: Methods and Protocols, (2016) 243-255.","DOI":"10.1007\/7651_2016_327"},{"key":"10.1016\/j.addr.2023.114831_b1920","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4049\/jimmunol.1301772","article-title":"Antigen-pulsed bone marrow\u2013derived and pulmonary dendritic cells promote Th2 cell responses and immunopathology in lungs during the pathogenesis of murine mycoplasma pneumonia","volume":"193","author":"Dobbs","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1925","doi-asserted-by":"crossref","unstructured":"D.W. Greening, R. Xu, H. Ji, B.J. Tauro, R.J. Simpson, A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods, Proteomic Profiling, Springer, 2015, pp. 179-209.","DOI":"10.1007\/978-1-4939-2550-6_15"},{"key":"10.1016\/j.addr.2023.114831_b1930","first-page":"61","article-title":"Drug loading techniques for exosome-based drug delivery systems","volume":"76","author":"Xi","year":"2021","journal-title":"Die Pharmazie-An Int. J. Pharmaceut. Sci."},{"key":"10.1016\/j.addr.2023.114831_b1935","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-023-01319-6","article-title":"Nanoparticle pre-treatment for enhancing the survival and activation of pulmonary macrophage transplant","author":"Jarai","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2023.114831_b1940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2023.114831_b1945","doi-asserted-by":"crossref","first-page":"20200186","DOI":"10.1002\/VIW.20200186","article-title":"Exosome therapeutics for COVID-19 and respiratory viruses","volume":"2","author":"Popowski","year":"2021","journal-title":"View"},{"key":"10.1016\/j.addr.2023.114831_b1950","doi-asserted-by":"crossref","unstructured":"K.D. Popowski, A. Moatti, G. Scull, D. Silkstone, H. Lutz, B. L\u00f3pez de Juan Abad, A. George, E. Belcher, D. Zhu, X. Mei, X. Cheng, M. Cislo, A. Ghodsi, Y. Cai, K. Huang, J. Li, A.C. Brown, A. Greenbaum, P.C. Dinh, K. Cheng, Inhalable dry powder mRNA vaccines based on extracellular vesicles, Matter, 5 (2022) 2960-2974.","DOI":"10.1016\/j.matt.2022.06.012"},{"key":"10.1016\/j.addr.2023.114831_b1955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-022-02900-5","article-title":"Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study","volume":"13","author":"Zhu","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.addr.2023.114831_b1960","doi-asserted-by":"crossref","unstructured":"M.m. Shi, Q.y. Yang, A. Monsel, J.y. Yan, C.x. Dai, J.y. Zhao, G.c. Shi, M. Zhou, X.m. Zhu, S.k. Li, Preclinical efficacy and clinical safety of clinical\u2010grade nebulized allogenic adipose mesenchymal stromal cells\u2010derived extracellular vesicles, J. Extracell. Vesic., 10 (2021) e12134.","DOI":"10.1002\/jev2.12134"},{"key":"10.1016\/j.addr.2023.114831_b1965","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41565-021-00923-2","article-title":"Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19","volume":"16","author":"Li","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2023.114831_b1970","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1975","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.2101058","article-title":"Innate immune memory and the host response to infection","volume":"208","author":"Sherwood","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2023.114831_b1980","doi-asserted-by":"crossref","unstructured":"B.M. Jarai, C.A. Fromen, Nanoparticle internalization promotes the survival of primary macrophages, bioRxiv, (2021) 2021.2004.2022.440822.","DOI":"10.1101\/2021.04.22.440822"},{"key":"10.1016\/j.addr.2023.114831_b1985","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1039\/D1TB00982F","article-title":"Hydrogel nanoparticle degradation influences the activation and survival of primary macrophages","volume":"9","author":"Jarai","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2023.114831_b1990","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150473","article-title":"The lung microbiome: progress and promise","volume":"131","author":"Whiteside","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2023.114831_b1995","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7861\/clinmedicine.17-6-525","article-title":"The lung microbiome in health and disease","volume":"17","author":"Moffatt","year":"2017","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.addr.2023.114831_b2000","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.immuni.2016.02.026","article-title":"Phagocytosis: an immunobiologic process","volume":"44","author":"Gordon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2023.114831_b2005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s41030-021-00167-4","article-title":"Digital inhalers for asthma or chronic obstructive pulmonary disease: a scientific perspective","volume":"7","author":"Chan","year":"2021","journal-title":"Pulm. Ther."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:38:17Z","timestamp":1759210697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23001461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":397,"alternative-id":["S0169409X23001461"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114831","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aerosol pulmonary immune engineering","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114831"}}